Arrhythmias & electrophysiology

Early recurrence of atrial tachyarrhythmia after catheter ablation and its associations with clinical outcomes, atrial fibrillation burden, and blanking period duration: a post hoc analysis of the CABANA trial

EuropacePublished Secondary analysis of the CABANA randomised trial

Authors' conclusion

ERAT was associated with higher risks of cardiovascular hospitalization and late atrial tachyarrhythmia recurrence in a time-dependent manner, supporting a shorter blanking period to better identify patients at risk of adverse rhythm outcomes.

Study context

Population
Patients from the CABANA trial who underwent catheter ablation with trial-specific ECG monitoring data
Participants
811 patients
Comparison
Early recurrence of atrial tachyarrhythmia (ERAT) vs no ERAT after catheter ablation for atrial fibrillation (AF)
  • ERATn = 567
Primary endpoint
Composite of:
  • All-cause mortality
  • Disabling stroke
  • Serious bleeding
  • Cardiac arrest
Follow-up
Median 4 years (IQR 2.5-5.2)
Methodological detailspost hoc analysis
  • Post hoc analysis

Primary result

As reported in the abstract

Primary composite outcome
  • ERAT: no increased risk of the primary composite outcome

Secondary outcomes

OutcomeaHR (95% CI)
CV hospitalization1.35 (1.07–1.71)
All-cause mortality or CV hospitalization1.33 (1.07–1.66)
Late atrial tachyarrhythmia recurrence1.35 (1.07–1.71)
Late atrial tachyarrhythmia recurrence · ERAT between 60 and 90 days after ablation1.80 (1.16–2.79)
ERAT incidence
69.9% · 567 of 567
Late atrial tachyarrhythmia recurrence — ROC optimal threshold for predicting late recurrence: 58 days
AUC 0.727

Original publication

Early recurrence of atrial tachyarrhythmia after catheter ablation and its associations with clinical outcomes, atrial fibrillation burden, and blanking period duration: a post hoc analysis of the CABANA trial. Europace. Published 7 July 2026. doi:10.1093/europace/euag173

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.